GlaxoSmithKline Files Drug Application for UMEC in US
OFT Alleges GlaxoSmithKline Concluded Pacts Which Infringed Competition Law
Thank you, very much and thank you all for joining us on this Q3 call of GSK . I am going to take you through just some headlines on the overall performance of the Company and RnD and then Julian Heslop, our CFO will take you through some more detail before we open up for questions.
My name is Simon, I'm your operator today. The format of the call will be some opening remarks from Andrew and Simon and (technical difficulty)
GlaxoSmithKline GSK reported solid second-quarter results on Wednesday that were largely in line with our expectations, and we don't anticipate any changes to our fair value estimate. Sales increased 10% from the prior year driven by strong sales of asthma medicine Advair, diabetes medicine ...
Research and Markets: Analyzing the Chemical Industry in the UK 2013
Theravance and Elan Enter Into a $1.0 Billion Royalty Participation Agreement
Elan, Theravance Enter Into $1.0 Billion Royalty Participation Pact
Elan Provides Additional Commentary on Elan/Theravance Royalty Participation Agreement
Cure Duchenne Hosts Drisapersen Update Webinar With GSK on May 6, 2013